Artigo de periodico-carta/editorial

Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria [Carta]: a multicenter real-life study (2021)

• Authors:
  • Debureaux, Pierre-Edouard
  • Kulasekararaj, Austin G.
  • Cacace, Fabiana
  • Silva, Bruno Garcia Peixoto Pires da
  • Calado, Rodrigo Tocantins
  • Barone, Federica
  • Fontbrune, Flore Sicre de
  • Prata, Pedro Henrique de Lima
  • Soret, Juliette
  • Sica, Michela
  • Notaro, Rosario
  • Scheinberg, Phillip
  • Mallikarjuna, Vasundhara
  • Gandhi, Shreyans
  • Large, Joanna
  • Risitano, Antonio M.
  • Latour, Régis Peffault de
  • Frieri, Camilla
• USP affiliated authors: RODRIGUES, RODRIGO DO TOCANTINS CALADO DE SALOMA - FMRP ; SILVA, BRUNO GARCIA PEIXOTO PIRES DA - FMRP ; PRATA, PEDRO HENRIQUE DE LIMA - FMRP
• Unidade: FMRP
• DOI: 10.1038/s41409-021-01372-0
• Subjects: ANTICORPOS MONOCLONAIS; HEMOGLOBINAS; ESTUDOS MULTICÊNTRICOS; TROMBOEMBOLISMO
• Language: Inglês
• Imprenta:
  • Publisher place: London
  • Date published: 2021
• Source:
  • Título: Bone Marrow Transplantation
  • ISSN: 0268-3369
  • Volume/Número/Paginação/Ano: v. 56, n. 10, p. 2600-2602, 2021

Informações sobre o DOI: 10.1038/s41409-021-01372-0 (Fonte: oaDOI API)
• Este periódico é de assinatura
• Este artigo NÃO é de acesso aberto
  
• Cor do Acesso Aberto: closed

---

Download do texto completo

Tipo	Nome	Link
	003234470.pdf

How to cite

A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

• ABNT

  DEBUREAUX, Pierre-Edouard et al. Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria [Carta]: a multicenter real-life study. Bone Marrow Transplantation. London: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1038/s41409-021-01372-0. Acesso em: 30 dez. 2025. , 2021

• APA

  Debureaux, P. -E., Kulasekararaj, A. G., Cacace, F., Silva, B. G. P. P. da, Calado, R. T., Barone, F., et al. (2021). Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria [Carta]: a multicenter real-life study. Bone Marrow Transplantation. London: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1038/s41409-021-01372-0

• NLM

  Debureaux P-E, Kulasekararaj AG, Cacace F, Silva BGPP da, Calado RT, Barone F, Fontbrune FS de, Prata PH de L, Soret J, Sica M, Notaro R, Scheinberg P, Mallikarjuna V, Gandhi S, Large J, Risitano AM, Latour RP de, Frieri C. Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria [Carta]: a multicenter real-life study [Internet]. Bone Marrow Transplantation. 2021 ; 56( 10): 2600-2602.[citado 2025 dez. 30 ] Available from: https://doi.org/10.1038/s41409-021-01372-0

• Vancouver

  Debureaux P-E, Kulasekararaj AG, Cacace F, Silva BGPP da, Calado RT, Barone F, Fontbrune FS de, Prata PH de L, Soret J, Sica M, Notaro R, Scheinberg P, Mallikarjuna V, Gandhi S, Large J, Risitano AM, Latour RP de, Frieri C. Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria [Carta]: a multicenter real-life study [Internet]. Bone Marrow Transplantation. 2021 ; 56( 10): 2600-2602.[citado 2025 dez. 30 ] Available from: https://doi.org/10.1038/s41409-021-01372-0

Últimas obras dos mesmos autores vinculados com a USP cadastradas na BDPI:

• Hyper-inflammation and complement in COVID-19
• A review of latest clinical practice guidelines for the management of cancer-associated thrombosis
• IPSS-M in myelodysplastic neoplasms arising from aplastic anemia and paroxysmal nocturnal hemoglobinuria [Carta]
• Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism. [Carta]: 2022 updated systematic review and meta-analysis of randomized controlled trials
• Clinical and molecular determinants of clonal evolution in aplastic anemia and paroxysmal nocturnal hemoglobinuria
• Immunogenetic, molecular and clinical determinants of clonal evolution in aplastic anemia and paroxysmal nocturnal hemoglobinuria
• Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy
• Targeting complement to treat paroxysmal nocturnal hemoglobinuria (PNH)
• Telomere dynamics in mice and humans
• A mutation in the H/ACA box of telomerase RNA component gene (TERC) in a young patient with myelodysplastic syndrome